Research Article

Relationship between Obesity Phenotypes and Cardiovascular Risk in a Chinese Cohort

Yueliang Hu1,†, Shuping Zheng2,†, Jiehui Zhao3, Isabella Tan4, Mark Butlin4, Alberto Avolio4, Junli Zuo1,4,*

1Department of Geriatric Medicine, Shanghai Jiatong School of Medicine, Ruijin Hospital North, Shanghai, China
2Department of General practice, Jiading District Jiangqiao Community Health Service Center, Shanghai, China
3Department of General practice, Daning Community Health Service Center, Shanghai, China
4Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, Australia

ABSTRACT

Objective: The changing living patterns in China are accompanied by an increase in prevalence of cardiovascular disease for which obesity is a significant factor. This study investigated the association between obesity phenotypes and risk of cardiovascular disease in a Chinese cohort.

Methods: A sample of 10,826 community-dwelling individuals aged 40–79 years (mean age 62.2 ± 12.0 years) were stratified by categories of body mass index (BMI) (normal weight: BMI < 24 kg/m²; overweight: BMI of 25–28 kg/m²; obese: BMI > 28 kg/m²) and metabolic status and divided into six phenotypes: (1) normal metabolic status and normal weight; (2) normal metabolic status and overweight; (3) normal metabolic status and obese; (4) normal weight and dysmetabolic status; (5) dysmetabolic status and overweight; (6) dysmetabolic status and obese. The Atherosclerotic Cardiovascular Disease (ASCVD) risk score was determined based on cardiovascular risk factors.

Results: Prevalence of overweight and obesity was 15.2% and 25.2% respectively. After adjusting for confounding factors, ASCVD score was significantly higher in men [Odds Ratio (OR): 9.796, 95% confidence interval (CI): 5.833–16.450; p < 0.001] and women [OR: 5.821, 95% CI: 4.253–7.968; p < 0.001] with obese and dysmetabolic status compared to normal. The odds of reporting ASCVD risk was significantly higher in men (OR: 3.432, 95% CI: 1.965–5.996; p < 0.001) and women (OR: 4.647, 95% CI: 3.327–6.491; p < 0.001) with obese and dysmetabolic status compared to those with obese and normal metabolic status. In addition, the odds of reporting ASCVD risk was significantly lower in men (OR: 0.317, 95% CI: 0.142–0.707; p = 0.005) and women (OR: 0.487, 95% CI: 0.320–0.739; p = 0.001) with the overweight–dysmetabolic status phenotype compared to those with an overweight–normal metabolic phenotype.

Conclusion: Obese dysmetabolic individuals had the highest ASCVD risk score in all phenotypes. When BMI category was overweight, BMI played a more important role than metabolic status, whereas when BMI category was obesity, risk was more affected by metabolic status.

HIGHLIGHTS

What is already known about this subject?
- Obesity presents a major risk for cardiovascular disease.
- Some studies provide evidence that obesity has better outcome compared to lean counterparts.

What does this study add?
- This study provides information that obese dysmetabolic individuals show the highest Atherosclerotic Cardiovascular Disease (ASCVD) risk score in all phenotypes in the whole cohort.
- This study also indicates that body mass index (BMI) plays a more important role for estimation of CV risk than metabolic status in overweight, whereas risk is more affected by metabolic status in obesity.

© 2020 Association for Research into Arterial Structure and Physiology. Publishing services by Atlantis Press International B.V. This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).

†These two authors contributed equally to this work.
*Corresponding author. Email: zuo-junli@163.com

Peer review under responsibility of the Association for Research into Arterial Structure and Physiology

Data availability statement: The data that support the findings of this study are available from the corresponding author, Junli Zuo, upon reasonable request.
1. INTRODUCTION

The prevalence of cardiovascular disease in China is rising, with the current population with coronary heart disease being estimated to be 11 million [1]. Cardiovascular disease is the major cause of death in the Chinese, and the burden of disease is severe. Overweight/obesity is a significant factor of cardiovascular risk [1]. Obesity affects almost one-third of the Chinese population and presents an increasingly serious health problem, with incidence of obesity in China ranking second in the world [2].

The association of obesity and cardiovascular disease has two aspects. Obesity is generally accepted as an independent risk factor of many cardiovascular diseases; however, in some groups the long-term prognoses for obese patients with cardiovascular disease are often better than for lean patients [3,4]. This paradox has been shown to exist in those undergoing coronary intervention, hypertension, heart failure and even the general population [5–9].

Metabolic syndrome is strongly associated with obesity [6], and is also a clear risk of coronary heart disease [1,10]. One-third of the Chinese population suffers from metabolic syndrome [11]. This situation is as serious as obesity.

Our study used the first severe 10-year Atherosclerotic Cardiovascular Diseases (ASCVD) score [12] to evaluate the risk in elderly Chinese, and analyzed the relationship of obesity and its related metabolic syndrome to ASCVD. We have attempted to avoid the influence of comorbidities, weakness and other influencing factors on the obesity paradox [5].

2. MATERIALS AND METHODS

2.1. Participants

A sample of 10,826 individuals aged 40–79 years (mean age 62.23 ± 12.0 years) was randomly selected from a community-dwelling eligible population and attended Jiading District Jianguo Community Health Service Center for laboratory and clinical investigation to determine their cardiovascular risk according to the American College of Cardiology/American Heart Association–ASCVD (ACC/AHA-ASCVD) risk score [13]. Exclusion criteria were those with cancer, CVD and any who had no data on obesity phenotypes. The study received approval by the Ethics Committee of Ruijin Hospital North, Shanghai Jiaotong University School of Medicine and all participants gave written informed consent.

2.2. Measurements

A standardized questionnaire was given to all participants and data collected for age, gender, smoking habits, medical history, consumption of alcohol and use of medications. Height was measured with a wall-mounted stadiometer to the nearest 0.5 cm without shoes and body weight was measured on a balance calibrated to the nearest 0.1 kg with minimum clothing and without shoes. Waist Circumference (WC) was measured at the maximum point of normal expiration at the midpoint between the iliac crest and lowest rib margin and the iliac crest with the subject standing. Measurements were made with an upstretched tape meter and recorded to the nearest 0.1 cm.

Blood samples were obtained after 12–14 h of overnight fasting. Serum Total Cholesterol (TC), Low-density Lipoprotein Cholesterol (LDL-C), High-density Lipoprotein Cholesterol (HDL-C), Triglycerides (TG), Fasting Blood Glucose (FBG), serum Uric Acid (UA), serum Creatinine (Cr), and glycosylated hemoglobin (HbA1c) were obtained from patient medical records. The Modification of Diet in Renal Disease (MDRD) formula [14] was used to calculate the estimated Glomerular Filtration Rate (eGFR). Glycosylated hemoglobin was determined by the BIO-RAD D-10TM kit. Seated blood pressure measurements were obtained in 12-h fasting individuals in the morning (7–9 am) with a standard manual sphygmomanometer after a 10-min rest and using the average of two readings in both arms. Pulse Pressure (PP) was calculated as the difference between Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) and Mean Arterial Pressure (MAP) was calculated as (DBP) + (PP)/3.

The ACC/AHA-ASCVD risk score was determined using values of TC, HDL-C, LDL-C, age, blood pressure, gender, presence of diabetes, and smoking status [13]. Status of current smoking was defined as having smoked the last cigarette within 1 week of when blood pressure measurements were taken.

2.3. Definitions

Weight and metabolic status were used to determine obesity phenotypes. Categories of overweight and obesity were based on thresholds of body mass index (BMI) with overweight and obesity defined as BMI between 24 and 28 kg/m² and >28 kg/m² respectively, according to published values for the Chinese population [15]. The presence of metabolic syndrome defined dysmetabolic status according to the definition of the Joint Interim Statement (JIS). JIS defines metabolic syndrome as the presence of any three of the following five risk factors: (1) abdominal obesity, defined as WC ≥80 cm in women and ≥80 cm in men [15]; (2) reduced HDL-C 40 mg/dl in men, <50 mg/dl in women or undergoing pharmacological treatment for reduced HDL-C; (3) elevated triglycerides (TG) levels ≥150 mg/dl or on pharmacological treatment for elevated TG; (4) elevated blood pressure (SBP ≥130 mmHg or DBP ≥85 mmHg) or on antihypertensive treatment; and (5) elevated FBG ≥100 mg/dl or on pharmacological treatment for elevated glucose [16]. There were six obesity phenotypes defined: (1) normal metabolic status and normal weight; (2) normal metabolic status and overweight; (3) normal metabolic status and obese; (4) dysmetabolic status and normal weight; (5) dysmetabolic status and overweight; (6) dysmetabolic status and obese.

The ACC/AHA-ASCVD risk score was defined as high risk when the score ≥7.5% and low risk when score <7.5% [14].

2.4. Statistical Analysis

Continuous variables are expressed as mean ± SD, and frequencies (percentage) are reported for categorical variables. Continuous and categorical variables were compared using t-test and Chi-square test respectively for males and females. To compare continuous and categorical variables among the groups of obesity phenotypes, Analysis of Variance (ANOVA) and Chi-square test respectively were used. Logistic regression analysis was used to compute the Odds Ratios (ORs). Sex specific ORs with 95% confidence intervals...
were computed for the total cohort and for males and females separately; model 1 was unadjusted, whereas model 2 was adjusted for age, sex and smoking status. Analyses were performed with SPSS 24.0 for Windows (SPSS Inc., Chicago, IL, USA). A two-sided \( p < 0.05 \) was considered statistically significant.

3. RESULTS

Mean age and BMI of participants were 62.2 ± 12.0 years and 24.6 ± 3.4 kg/m\(^2\) respectively. Table 1 shows baseline characteristics. Of the 10,826 participants, 4683 were male (43.3%). Mean age for males and females was 63.0 ± 11.8 and 61.7 ± 12.1 years respectively. The male population had a significantly greater height, larger waist circumference, higher Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP), greater BMI, higher FBG, higher glycosylated hemoglobin, higher triglycerides, lower total cholesterol driven by lower HDL-C and lower LDL-C, lower eGFR, lower uric acid, higher ASCVD risk score, and higher rate of left ventricular hypertrophy. None of the women were smokers compared to 37.2% of men.

Prevalence of overweight and obesity was 15.2% and 25.2% respectively. The least and most common obesity phenotypes were and overweight–dysmetabolic status (2.1% in men and 1.3% in women) and normal weight–normal metabolic status (19.2% in men and 36.2% of men).

Table 3 shows the odds of reporting ASCVD risk for weight, metabolic status, and different obesity phenotypes in men and women separately. After adjusting for confounding variables, the OR of reporting ASCVD risk were significantly higher in both men (OR: 6.133, 95% CI: 4.524–8.315; \( p < 0.001 \)) and women (OR: 3.708, 95% CI: 3.123–4.402; \( p < 0.001 \)) with dysmetabolic status, compared those with normal metabolic status. For weight status, both obese men (OR: 4.221, 95% CI: 2.817–6.326; \( p < 0.001 \)) and women (OR: 2.628, 95% CI: 2.069–3.339; \( p < 0.001 \)) were more likely to report a higher ASCVD risk score compared to their normal weight counterparts; both overweight men (OR: 3.124, 95% CI: 2.322–4.203; \( p < 0.001 \)) and women (OR: 1.567, 95% CI: 1.311–1.872; \( p < 0.001 \)) were more likely to report higher ASCVD risk score compared to their normal weight counterparts.

For obesity phenotypes and after adjusting for confounding variables, the odds of reporting ASCVD risk was significantly higher in men (OR: 9.796, 95% CI: 5.833–16.450; \( p < 0.001 \), Table 4) and women (OR: 5.821, 95% CI: 4.253–7.968; \( p < 0.001 \), Table 5) with obese dysmetabolic status, in men (OR: 9.542, 95% CI: 5.991–15.197; \( p < 0.001 \)) and women (OR: 4.875, 95% CI: 3.697–6.429; \( p < 0.001 \)) with normal weight–dysmetabolic status, in men (OR: 7.361, 95% CI: 4.415–12.272; \( p < 0.001 \)) and women (OR: 2.770, 95% CI: 2.136–3.592; \( p < 0.001 \)) with overweight–normal metabolic status, compared to those with normal weight–normal metabolic status. In addition, in men the odds of reporting ASCVD risk was significantly higher with the overweight–dysmetabolic status phenotype (OR: 2.766, 95% CI: 1.418–5.394; \( p = 0.003 \)) and the obese–normal metabolic status phenotype (OR: 2.830, 95% CI: 1.946–4.116; \( p < 0.001 \)) compared to those with a normal weight–normal metabolic phenotype. However, there was no statistical significance among women.

The odds of reporting ASCVD risk was significantly higher in men (OR: 3.432, 95% CI: 1.965–5.996; \( p < 0.001 \)) and women (OR: 4.647, 95% CI: 3.327–6.491; \( p < 0.001 \)) with obese–dysmetabolic

Table 1. Characteristics of the study subjects

| Characteristics                  | Total (n = 10,826) | Men (n = 4683) | Women (n = 6143) | p-value |
|----------------------------------|-------------------|---------------|------------------|---------|
| Age (years)                      | 62.23 ± 12.0      | 62.97 ± 11.81 | 61.67 ± 12.14    | <0.001  |
| Height (cm)                      | 159.80 ± 8.58     | 166.28 ± 6.68 | 154.87 ± 6.27    | <0.001  |
| Weight (kg)                      | 62.95 ± 10.63     | 68.73 ± 10.14 | 58.54 ± 8.71     | <0.001  |
| Waist (cm)                       | 83.19 ± 9.30      | 86.22 ± 8.68  | 80.89 ± 9.09     | <0.001  |
| BMI (kg/m²)                      | 24.60 ± 3.35      | 24.84 ± 3.27  | 24.41 ± 3.41     | <0.001  |
| Smoking, n (%)                   | 1742 (16.1)       | 1742 (37.2)   | 0 (0)            | <0.001  |
| Glucose (mmol/L)                 | 5.36 ± 1.59       | 5.43 ± 1.67   | 5.31 ± 1.52      | <0.001  |
| HbA1c (%)                        | 5.79 ± 0.97       | 5.83 ± 1.03   | 5.76 ± 10.91     | 0.001   |
| Triglycerides (mmol/L)           | 1.63 ± 1.23       | 1.67 ± 1.28   | 1.61 ± 1.19      | 0.001   |
| Total cholesterol (mmol/L)       | 5.01 ± 0.99       | 4.79 ± 0.94   | 5.18 ± 0.99      | <0.001  |
| HDL-C (mmol/L)                   | 3.18 ± 0.86       | 3.06 ± 0.82   | 3.28 ± 0.87      | <0.001  |
| LDL-C (mmol/L)                   | 1.40 ± 0.36       | 1.29 ± 0.33   | 1.48 ± 0.36      | <0.001  |
| Creatinine (µmol/L)              | 71.76 ± 20.96     | 82.29 ± 18.73 | 63.73 ± 18.92    | <0.001  |
| eGFR [ml/(min·1.73 m²)]          | 87.92 ± 15.99     | 86.44 ± 15.22 | 89.05 ± 16.47    | <0.001  |
| Uric acid (µmol/L)               | 317.86 ± 83.94    | 358.65 ± 81.97| 286.77 ± 71.15   | <0.001  |
| ASCVD10-y (%)                    | 14.03 ± 12.12     | 19.53 ± 12.46 | 10.00 ± 11.11    | <0.001  |
| SBP (mmHg)                       | 136.43 ± 19.63    | 137.16 ± 18.74| 135.87 ± 20.27   | 0.001   |
| DBP (mmHg)                       | 85.55 ± 10.38     | 87.57 ± 10.54 | 84.01 ± 9.99     | 0.001   |
| PP (mmHg)                        | 50.88 ± 16.03     | 49.59 ± 14.87 | 51.86 ± 16.79    | <0.001  |
| MAP (mmHg)                       | 102.51 ± 11.97    | 104.10 ± 11.91| 101.29 ± 11.87   | <0.001  |
| HR (bpm)                         | 73.98 ± 11.34     | 71.74 ± 11.31 | 75.68 ± 11.06    | <0.001  |
| LVH, n (%)                       | 686 (6.3)         | 481 (10.3)    | 205 (3.3)        | <0.001  |

Data are mean ± SD or percentage as marked. p-value: independent t-test analysis of variance for numeric variables and Chi-square test for categoric variables.

eGFR is an estimate of GFR for the modified MDRD formula, estimated glomerular filtration rate; HbA1c, glycosylated hemoglobin; LDL-C, low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol; ASCVD, atherosclerotic cardiovascular diseases; SBP, systolic blood pressure; DBP, diastolic blood pressure; PP, pulse pressure; MAP, mean arterial pressure; HR, heart rate; LVH, left ventricular hypertrophy.
Table 2  Characteristics of the study subjects in different metabolic status

| Characteristics | Normal metabolic status | Dysmetabolic status | p-value |
|-----------------|-------------------------|---------------------|---------|
|                 | (n = 5028)              | (n = 1150)          | (n = 1667) |
| Age (years)     | 60.37 ± 12.94           | 64.31 ± 10.21       | 62.04 ± 11.67 |
| Male gender, n (%) | 2081 (41.39)           | 435 (37.83)         | 814 (48.89) |
| Height (cm)     | 160.08 ± 8.31           | 159.85 ± 8.68       | 159.65 ± 8.26 |
| Weight (kg)     | 56.91 ± 7.74            | 59.23 ± 7.65        | 67.03 ± 7.24 |
| Waist (cm)      | 77.19 ± 7.08            | 82.31 ± 6.63        | 85.71 ± 5.69 |
| BMI (kg/m²)     | 22.14 ± 1.90            | 23.11 ± 1.48        | 26.23 ± 0.84 |
| Smoking, n (%)  | 664 (13.21)             | 167 (14.52)         | 290 (17.40) |
| Glucose (mmol/L) | 4.98 ± 1.15             | 2.01 ± 1.95         | 5.04 ± 1.26 |
| Total cholesterol (mmol/L) | 4.94 ± 0.95       | 5.12 ± 1.00         | 4.99 ± 0.93 |
| LDL-C (mmol/L)  | 3.11 ± 0.83             | 3.25 ± 0.92         | 3.23 ± 0.82 |
| Triglycerides (mmol/L) | 1.22 ± 0.72            | 2.50 ± 1.67         | 1.35 ± 0.64 |
| AST (U/L)       | 20.2 ± 13.9             | 20.3 ± 6.3          | 21.7 ± 7.6 |
| ALT (U/L)       | 16.2 ± 18.9             | 18.4 ± 9.3          | 21.8 ± 12.5 |
| HR (bpm)        | 72.1 ± 10.5             | 70.8 ± 9.9          | 71.6 ± 10.1 |
| PP (mmHg)       | 41.2 ± 9.7              | 43.6 ± 9.7          | 44.8 ± 10.5 |
| Glucose (mmol/L) | 4.98 ± 1.15             | 6.02 ± 1.95         | 5.04 ± 1.16 |
| Total cholesterol (mmol/L) | 4.94 ± 0.95       | 5.12 ± 1.00         | 4.99 ± 0.93 |
| LDL-C (mmol/L)  | 3.11 ± 0.83             | 3.25 ± 0.92         | 3.23 ± 0.82 |
| Triglycerides (mmol/L) | 1.22 ± 0.72            | 2.50 ± 1.67         | 1.35 ± 0.64 |
| AST (U/L)       | 20.2 ± 13.9             | 20.3 ± 6.3          | 21.7 ± 7.6 |
| ALT (U/L)       | 16.2 ± 18.9             | 18.4 ± 9.3          | 21.8 ± 12.5 |
| HR (bpm)        | 72.1 ± 10.5             | 70.8 ± 9.9          | 71.6 ± 10.1 |
| PP (mmHg)       | 41.2 ± 9.7              | 43.6 ± 9.7          | 44.8 ± 10.5 |

Data are mean ± SD or percentage as marked. p-value: independent t-test analysis of variance for numeric variables and Chi-square test for categoric variables. eGFR is an estimate of GFR for the modified MDRD formula, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; LDL-C, low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol; ASCVD, atherosclerotic cardiovascular diseases; SBP, systolic blood pressure; DBP, diastolic blood pressure; PP, pulse pressure; MAP, mean arterial pressure; HR, heart rate; ALT, alanine transaminase; AST, Aspartate transaminase; LVH, left ventricular hypertrophy.

Table 3  Odds ratios and 95% confidence intervals for ASCVD among men and women

| Phenotype | ASCVD (G) | p-value | ASCVD (N) | p-value |
|-----------|-----------|---------|-----------|---------|
| Model 1   | Normal metabolic status | (Ref.)   | <0.001   | 1.046 (1.042–1.050) | <0.001 |
| Model 2   | Normal metabolic status | (Ref.)   | <0.001   | 1.077 (1.070–1.084) | <0.001 |
| Model 1   | Normal weight | (Ref.)   | <0.001   | 1.007 (1.003–1.011) | <0.001 |
| Model 2   | Normal weight | (Ref.)   | <0.001   | 1.039 (1.034–1.044) | <0.001 |
| Model 1   | Normal weight and metabolic status | (Ref.)   | <0.001   | 1.030 (1.023–1.036) | <0.001 |
| Model 2   | Normal weight and metabolic status | (Ref.)   | <0.001   | 1.044 (1.036–1.052) | <0.001 |
| Model 1   | Overweight and normal metabolic status | (Ref.)   | <0.001   | 1.040 (1.035–1.046) | <0.001 |
| Model 2   | Overweight and normal metabolic status | (Ref.)   | <0.001   | 1.017 (1.012–1.023) | <0.001 |
| Model 1   | Overweight and metabolic status | (Ref.)   | <0.001   | 1.054 (1.049–1.060) | <0.001 |
| Model 2   | Overweight and metabolic status | (Ref.)   | <0.001   | 1.031 (1.023–1.039) | <0.001 |
| Model 1   | Obese and normal metabolic status | (Ref.)   | <0.001   | 1.055 (1.049–1.061) | <0.001 |
| Model 2   | Obese and normal metabolic status | (Ref.)   | <0.001   | 1.063 (1.053–1.073) | 0.001 |
| Model 1   | Obese and metabolic status | (Ref.)   | <0.001   | 1.015 (1.006–1.024) | <0.001 |
| Model 2   | Obese and metabolic status | (Ref.)   | <0.001   | 1.076 (1.066–1.086) | <0.001 |
| Model 1   | Obese and dysmetabolic status | (Ref.)   | <0.001   | 1.011 (0.998–1.024) | 0.110 |
| Model 2   | Obese and dysmetabolic status | (Ref.)   | <0.001   | 1.082 (1.072–1.093) | <0.001 |

(Continued)
Table 3  Odds ratios and 95% confidence intervals for ASCVD among men and women—Continued

| Phenotype                        | ASCVD (G) | p-value | ASCVD (N) | p-value |
|----------------------------------|-----------|---------|-----------|---------|
|                                  | OR (95% CI)|         | OR (95% CI)|         |
| Obese and normal metabolic status (Ref.) | (Ref.) |         | (Ref.) |         |
| Normal weight and dysmetabolic status | 4.308 (3.326–5.581) | <0.001 | 1.075 (1.062–1.089) | <0.001 |
| Overweight and dysmetabolic status | 1.308 (0.926–1.848) | 0.128 | 0.996 (0.980–1.013) | 0.661 |
| Obese and dysmetabolic status    | 4.785 (3.619–6.328) | <0.001 | 1.043 (1.036–1.051) | <0.001 |
| Overweight and normal metabolic status (Ref.) | (Ref.) |         | (Ref.) |         |
| Overweight and dysmetabolic status | 0.461 (0.322–0.660) | <0.001 | 0.933 (0.915–0.951) | <0.001 |

Model 1: Unadjusted. Model 2: Adjusting for age, sex, smoking. Ref, Reference; G, categorical variables; N, continuous variables.

Table 4  Odds ratios and 95% confidence intervals for ASCVD among men

| Phenotype                                | ASCVD (G) | p-value | ASCVD (N) | p-value |
|------------------------------------------|-----------|---------|-----------|---------|
|                                          | OR (95% CI)|         | OR (95% CI)|         |
| Model 1 Normal metabolic status          | (Ref.) |         | (Ref.) |         |
| Dysmetabolic status                      | 2.640 (2.109–3.304) | <0.001 | 1.046 (1.040–1.052) | <0.001 |
| Model 2 Normal metabolic status          | (Ref.) |         | (Ref.) |         |
| Dysmetabolic status                      | 6.133 (4.524–8.315) | <0.001 | 1.111 (1.099–1.122) | <0.001 |
| Model 1 Normal weight                    | (Ref.) |         | (Ref.) |         |
| Overweight                               | 1.900 (1.539–2.347) | <0.001 | 1.024 (1.018–1.030) | <0.001 |
| Obese                                    | 2.234 (1.649–3.025) | <0.001 | 1.038 (1.030–1.045) | <0.001 |
| Model 2 Normal weight                    | (Ref.) |         | (Ref.) |         |
| Overweight                               | 3.124 (2.322–4.203) | <0.001 | 1.047 (1.037–1.057) | <0.001 |
| Obese                                    | 4.221 (2.817–6.326) | <0.001 | 1.066 (1.054–1.078) | <0.001 |
| Model 1 Normal weight and normal metabolic status (Ref.) | (Ref.) |         | (Ref.) |         |
| Overweight and normal metabolic status   | 2.582 (1.781–3.744) | <0.001 | 1.043 (1.033–1.052) | <0.001 |
| Obese and normal metabolic status        | 1.608 (1.256–2.059) | <0.001 | 1.016 (1.008–1.024) | <0.001 |
| Normal weight and dysmetabolic status    | 3.503 (2.479–4.949) | <0.001 | 1.051 (1.042–1.059) | <0.001 |
| Overweight and dysmetabolic status       | 1.863 (1.186–2.927) | <0.001 | 1.026 (1.014–1.038) | <0.001 |
| Obese and dysmetabolic status            | 3.065 (2.074–4.529) | <0.001 | 1.055 (1.046–1.065) | <0.001 |
| Model 2 Normal weight and normal metabolic status (Ref.) | (Ref.) |         | (Ref.) |         |
| Overweight and normal metabolic status   | 7.361 (4.415–12.272) | <0.001 | 1.096 (1.080–1.113) | <0.001 |
| Obese and normal metabolic status        | 2.830 (1.946–4.116) | <0.001 | 1.033 (1.020–1.046) | <0.001 |
| Normal weight and dysmetabolic status    | 9.542 (5.991–15.197) | <0.001 | 1.110 (1.095–1.126) | <0.001 |
| Overweight and dysmetabolic status       | 2.766 (1.418–5.394) | 0.003 | 1.026 (1.006–1.045) | 0.010 |
| Obese and dysmetabolic status            | 9.796 (5.833–16.450) | <0.001 | 1.121 (1.104–1.139) | <0.001 |
| Model 1 Normal weight and normal metabolic status (Ref.) | (Ref.) |         | (Ref.) |         |
| Overweight and normal metabolic status   | 3.364 (2.010–5.630) | <0.001 | 1.095 (1.076–1.114) | <0.001 |
| Obese and normal metabolic status        | 9.310 (4.561–1.900) | 0.844 | 0.996 (0.972–1.021) | 0.750 |
| Normal weight and dysmetabolic status    | 3.432 (1.965–5.996) | <0.001 | 1.112 (1.090–1.135) | <0.001 |
| Overweight and normal metabolic status   | 0.317 (0.142–0.707) | 0.005 | 0.920 (0.895–0.947) | <0.001 |

Model 1: Unadjusted. Model 2: Adjusting for age, sex, smoking. Ref, Reference; G, categorical variables; N, continuous variables.

status, compared to those with obese–normal metabolic status, all adjusted for confounding variables. The odds of reporting ASCVD risk was significantly lower in men (OR: 0.317, 95% CI: 0.142–0.707; \( p = 0.005 \)) and women (OR: 0.487, 95% CI: 0.320–0.739; \( p = 0.001 \)) with the overweight–dysmetabolic status phenotype compared to those with an overweight-normal metabolic phenotype.

4. DISCUSSION

Our study suggested that obesity with metabolic syndrome in all groups have the highest risk of ASCVD, and this result is not unexpected. Obesity and metabolic syndrome are risk factors for ASCVD, and their additive effects may further increase the risk of ASCVD. Different factors such as the elevated risk of complications associated with obesity (type 2 diabetes, hyperlipidemia, hypertension). Cytokines secret by adipose tissue (e.g., tumor necrosis factor, interleukin-6, and fibrinogen activation inhibitors), increased heart and blood flow load by adipose tissue, insulin resistance and lipid toxicity would increase the risk of ASCVD in obesity [17,18].

Metabolic syndrome has been found to be associated with ASCVD, and its effects are independent of insulin resistance [19]. Metabolic risk factors (elevated blood pressure, elevated blood glucose, atherogenic dyslipidemia, a prothrombotic state and a proinflammatory state) affect the atherogenic process. But because of the
1. The above benefits may offset metabolic needs, adipose tissue productions including benefits to tissue function, nutritional reserves for acute stress events and increased metabolic state, better cognitive function with adipose tissue, growing evidence suggests benefits. These may involve earlier treatment for abnormal metabolic state, leading to earlier treatment for abnormal metabolic syndrome.

2. Elevated blood pressure may also influence vascular endothelial function, making cholesterol more likely to be deposited on the endothelium. Elevated blood glucose enhances effects of oxidative stress in the arterial wall, glycosylation of arterial wall proteins, deposition of advanced glycation end products in the arterial wall, and activation of protein kinase C. All these lead to atherosclerosis. Inflammatory conditions may also accelerate arterial endothelial dysfunction, leading to the formation of atherosclerosis.

3. Our study suggested that ASCVD risk is also higher in patients with obesity and normal metabolic status compared to patients with normal weight metabolic syndrome, indicating that abnormal metabolic state has a greater impact on ASCVD than obesity, which may be associated with the mechanism of the obesity paradox. The effects of metabolic syndrome have been discussed above. Current investigations on the obesity paradox suggested that obesity may have some benefits. These may involve earlier treatment for abnormal metabolic state, better cognitive function with adipose tissue, nutritional reserves for acute stress events and increased metabolic needs, adipose tissue productions including beneficial hormones and cytokines.

4. The adverse effects of obesity. Therefore, obese individuals without metabolic syndrome may be obese and relatively healthy. Studies have confirmed that endothelial function with obesity may still be normal. Obese insulin-sensitive individuals had a favorable metabolic profile compared to the obese insulin-resistant group. The state of healthy obesity may be unstable and affected by lifestyle, and may progress to metabolic syndrome so that it increases the risk of ASCVD.

5. It should be noted that the assessment of metabolic syndrome does not include all major risks of ASCVD, such as age, smoking status and lipid levels, so this assessment cannot be used to replace ASCVD risk assessment.

6. According to gender analysis, there was no statistical difference in the risk of ASCVD in women with different weight and metabolic status. However, in the case of metabolic abnormalities, the risk of ASCVD in women increased significantly, suggesting that the effects of metabolic abnormalities on women were more pronounced than obesity. Compared to men, women’s physiological structure, hormone levels, and vascular endothelial function have unique characteristics. A study showed that serum Follicle-stimulating Hormone (FSH) levels were negatively associated with 10-year ASCVD risk in postmenopausal women regardless of central obesity. FSH and numerous metabolic risks perturbations were independent of the measure of adiposity.

---

**Table 5** Odds ratios and 95% confidence intervals for ASCVD among women

| Phenotype                                      | ASCVD (G) | p-value | ASCVD (N) | p-value |
|------------------------------------------------|-----------|---------|-----------|---------|
| Women                                          |           |         |           |         |
| Model 1 Normal metabolic status (Ref.) (Ref.)  |           |         |           |         |
| Dysmetabolic status                            | 4.085 (3.621–4.609) | <0.001 | 1.071 (1.064–1.078) | <0.001 |
| Model 2 Normal metabolic status (Ref.) (Ref.)  |           |         |           |         |
| Dysmetabolic status                            | 3.708 (3.123–4.402) | <0.001 | 1.067 (1.057–1.078) | <0.001 |
| Model 1 Normal weight (Ref.) (Ref.)            |           |         |           |         |
| Overweight                                     | 1.873 (1.691–2.124) | <0.001 | 1.030 (1.024–1.037) | <0.001 |
| Obese                                          | 3.456 (2.920–4.090) | <0.001 | 1.051 (1.043–1.059) | <0.001 |
| Model 2 Normal weight (Ref.) (Ref.)            |           |         |           |         |
| Overweight                                     | 1.567 (1.311–1.872) | <0.001 | 1.020 (1.011–1.030) | <0.001 |
| Obese                                          | 2.628 (2.069–3.339) | <0.001 | 1.032 (1.021–1.043) | <0.001 |
| Model 1 Normal weight and normal metabolic status (Ref.) (Ref.) | | | | |
| Overweight and normal metabolic status          | 3.412 (2.851–4.083) | <0.001 | 1.062 (1.052–1.071) | <0.001 |
| Obese and normal metabolic status               | 1.270 (1.073–1.504) | 0.006  | 1.015 (1.006–1.024) | <0.001 |
| Normal weight and dysmetabolic status           | 5.396 (4.475–6.508) | <0.001 | 1.075 (1.066–1.085) | <0.001 |
| Overweight and dysmetabolic status              | 2.778 (2.198–3.564) | <0.001 | 1.044 (1.032–1.056) | <0.001 |
| Obese and dysmetabolic status                  | 5.848 (4.733–7.226) | <0.001 | 1.078 (1.065–1.086) | <0.001 |
| Model 2 Normal weight and normal metabolic status (Ref.) (Ref.) | | | | |
| Overweight and normal metabolic status          | 2.770 (2.136–3.592) | <0.001 | 1.053 (1.039–1.067) | <0.001 |
| Obese and normal metabolic status               | 0.995 (0.790–1.253) | 0.966  | 1.002 (0.988–1.016) | 0.785  |
| Normal weight and dysmetabolic status           | 4.875 (3.697–6.429) | <0.001 | 1.063 (1.049–1.077) | <0.001 |
| Overweight and dysmetabolic status              | 1.372 (0.939–2.003) | 0.102  | 1.005 (0.987–1.024) | 0.589  |
| Obese and dysmetabolic status                  | 5.821 (4.253–7.968) | <0.001 | 1.067 (1.052–1.082) | <0.001 |
| Obese and normal metabolic status               | (Ref.) (Ref.) | | | |
| Normal weight and dysmetabolic status           | 4.117 (3.020–5.611) | <0.001 | 1.075 (1.054–1.096) | <0.001 |
| Overweight and dysmetabolic status              | 1.288 (0.863–1.923) | 0.215  | 1.002 (0.979–1.026) | 0.851  |
| Obese and dysmetabolic status                  | 4.647 (3.327–6.491) | <0.001 | 1.080 (1.058–1.101) | <0.001 |
| Overweight and normal metabolic status          | (Ref.) (Ref.) | | | |
| Overweight and dysmetabolic status              | 0.487 (0.320–0.739) | 0.001  | 0.943 (0.919–0.968) | <0.001 |

Model 1: Unadjusted. Model 2: Adjusting for age, sex, smoking. Ref, Reference; G, categorical variables; N, continuous variables.
women’s ASCVD risk factors may be more affected by hormone levels than obesity. However, further investigations are needed due to the large number of confounding factors.

In addition, our study suggested that overweight with abnormal metabolism and obesity with normal metabolism cannot determine the risk of ASCVD. When BMI is due to overweight, BMI is more important than metabolic factors. When BMI is due to obesity, metabolic factors are more important than BMI.

The above results suggest that in addition to metabolic factors, the predictive value of obesity for ASCVD varies. This may be because BMI alone cannot effectively determine the type of obesity and estimate its risk. A study [30] suggested that abdominal obesity indices (waist-to-height ratio), but not BMI, predicted prevalent ASCVD and its risk factors in this elderly Chinese population. Another study in Filipino women also yielded similar results [30].

Both men and women may experience decreased muscle mass and loss of bone structure with age [31], which affect the accuracy of BMI. The presence of abdominal obesity is more highly correlated with metabolic risk factors than is an elevated BMI [10]. Therefore, it is easier to determine the type of metabolism and ASCVD risk with abdominal obesity indices, visceral adiposity index [26] and percent body fat [27]. The China-PAR Project [32] developed effective tools including waist circumference with good performance for 10-year ASCVD risk among the Chinese population. Furthermore, as described above, adipose tissue may have both beneficial and adverse effects, and thus the confounding effects of obesity/overweight and metabolic abnormalities make it difficult to determine the clinical endpoint.

In conclusion, our study extended our previous observations [33] and suggested that abnormal metabolic status may have a greater impact on ASCVD than obesity. “Obesity and health” may be one of the mechanisms of the obesity paradox. However, further studies are needed due to the numerous factors of metabolic syndrome and mutual influence.

CONFLICTS OF INTEREST
The authors declare they have no conflicts of interest.

AUTHORS’ CONTRIBUTION
AA and J. Zuo contributed in study conceptualization and writing (review and editing) the manuscript. J. Zuo, YH, SZ and J. Zhao contributed in data curation, formal analysis and writing (original draft). J. Zuo and SZ contributed in funding acquisition and project administration. AA, J. Zuo, IT and MB contributed in supervised the project. J. Zuo, YH and SZ contributed in formal analysis and writing (original draft) the manuscript.

FUNDING
This project was supported by the National Natural Science Foundation of China (Grant No. 81500190), and Shanghai Municipal Commission of Health and Family Planning (Grant No. 201740128; No. 201840087; No. 20184Y0100), Shanghai Jiating Science and Technology Committee (JDKW-2017-W12).

ACKNOWLEDGMENTS
We gratefully acknowledge the invaluable assistance of the physicians of the Department of Geriatric Medicine Ruijin Hospital North, Shanghai Jiaotong University School of Medicine and Jiading District Jiangqiao Community Health Service Center; the study would not have been possible without their support.

REFERENCES
[1] Stevens J, Truesdale KP, Katz EG, Cai J. Impact of body mass index on incident hypertension and diabetes in Chinese Asians, American Whites, and American Blacks: The People’s Republic of China Study and the Atherosclerosis Risk in Communities Study. Am J Epidemiol 2008;167:1365–74.
[2] Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014;384:766–81.
[3] Jordan J, Toplak H, Grassi G, Yumuk V, Kotsis V, Engeli S, et al. Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension: obesity and heart failure. J Hypertens 2016;34:1678–88.
[4] Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. Arterioscler Thromb Vasc Biol 2006;26:968–76.
[5] Holroyd EW, Sirker A, Kwok CS, Kontopantelis E, Ludman PF, De Belder MA, et al. The relationship of body mass index to percutaneous coronary intervention outcomes: does the obesity paradox exist in contemporary percutaneous coronary intervention cohorts? Insights from the British Cardiovascular Intervention Society Registry. JACC Cardiovasc Interv 2017;10:1283–92.
[6] Wassertheil-Smoller S, Fann C, Allman RM, Black HR, Camel GH, Davis B, et al. Relation of low body mass to death and stroke in the systolic hypertension in the elderly program. The SHEP Cooperative Research Group. Arch Intern Med 2000;160:494–500.
[7] Jerant A, Franks P. Body mass index, diabetes, hypertension, and short-term mortality: a population-based observational study, 2000–2006. J Am Board Fam Med 2012;25:422–31.
[8] Pokharel Y, Sun W, Virani SS, Nambi V, Hoogeveen RC, Chang PP, et al. Myocardial injury, obesity, and the obesity paradox: the ARIC Study. JACC Heart Fail 2017;5:56–63.
[9] Uretsky S, Messerli FH, Bangalore S, Champion A, Cooper-Dehoff RM, Zhou Q, et al. Obesity paradox in patients with hypertension and coronary artery disease. Am J Med 2007;120:863–70.
[10] Grundy SM. Metabolic syndrome: therapeutic considerations. Handb Exp Pharmacol 2005;170:107–33.
[11] Lu J, Wang L, Li M, Xu Y, Jiang Y, Wang W, et al. Metabolic syndrome among adults in China: the 2010 China noncommunicable disease surveillance. J Clin Endocrinol Metab 2017;102:507–15.
[12] Eckel RH, Jakicic JM, Ard JD, de Jesus JM, Houston Miller N, Hubbard VS, et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63:2960–84.
Goff DC, Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB, Gibbons R, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63:2935–59.

Greene T, Bourgoignie JJ, Habwe V, Kusek JW, Snetselaar LG, Soucie JM, et al. Baseline characteristics in the modification of diet in Renal Disease Study. J Am Soc Nephrol 1993;4:1221–36.

Zhou BF, Cooperative Meta-Analysis Group of the Working Group on Obesity in China. Predictive values of body mass index and waist circumference for risk factors of certain related diseases in Chinese adults—study on optimal cut-off points of body mass index and waist circumference in Chinese adults. Biomed Environ Sci 2002;15:83–96.

Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JJ, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640–5.

Jee SH, Jo J. Linkage of epidemiologic evidence with the clinical aspects of metabolic syndrome. Korean Circ J 2012;42:371–8.

Katz EG, Stevens J, Truesdale KP, Cai J, North KE, Steffen LM. Associations of body mass index with incident hypertension in American white, American black and Chinese Asian adults in early and middle adulthood: the Coronary Artery Risk Development in Young Adults (CARDIA) study, the Atherosclerosis Risk in Communities (ARIC) study and the People's Republic of China (PRC) study. Asia Pac J Clin Nutr 2013;22:626–34.

Yun JE, Won S, Sung J, Jee SH. Impact of metabolic syndrome independent of insulin resistance on the development of cardiovascular disease. Circ J 2012;76:2443–8.

Aronson D, Rayfield EJ. How hyperglycemia promotes atherosclerosis: molecular mechanisms. Cardiovasc Diabetol 2002;1:1.

Wu S, Yang YM, Zhu J, Wan HB, Wang J, Zhang H, et al. Impact of age on the association between body mass index and all-cause mortality in patients with atrial fibrillation. J Nutr Health Aging 2017;21:1125–32.

Cheng FW, Gao X, Mitchell DC, Wood C, Rolston DD, Still CD, et al. Metabolic health status and the obesity paradox in older adults. J Nutr Gerontol Geriatr 2016;35:161–76.

Bucholz EM, Beckman AL, Krumholz HA, Krumholz HM; Dr. Bucholz was affiliated with the Yale School of Medicine and Yale School of Public Health during the time that the work was conducted. Excess weight and life expectancy after acute myocardial infarction: the obesity paradox reexamined. Am Heart J 2016;172:173–81.

Fahs CA, Smith DL, Horn GP, Agiovlasitis S, Rossow LM, Echols G, et al. Impact of excess body weight on arterial structure, function, and blood pressure in firefighters. Am J Cardiol 2009;104:1441–5.

Khawaja KI, Mian SA, Fatima A, Tahir GM, Khan FF, Burney S, et al. Phenotypic and metabolic dichotomy in obesity: clinical, biochemical and immunological correlates of metabolically divergent obese phenotypes in healthy South Asian adults. Singapore Med J 2018;59:431–8.

Oh SK, Cho AR, Kwon YJ, Lee HS, Lee JW. Derivation and validation of a new visceral adiposity index for validating visceral obesity and cardiometabolic risk in a Korean population. PLoS One 2018;13:e0203787.

Li K, Ochoa E, Lipsey T, Nelson T. Correlates of atherosclerotic cardiovascular disease risk in older Colorado firefighters. Occup Med 2018;68:51–5.

Pichler G, Martinez F, Vicente A, Solaz E, Calaforra O, Lurbe E, et al. Influence of obesity in central blood pressure. J Hypertens 2015;33:308–13.

Wang N, Shao H, Chen Y, Xia F, Chi C, Li Q, et al. Follicle-stimulating hormone, its association with cardiometabolic risk factors, and 10-year risk of cardiovascular disease in postmenopausal women. J Am Heart Assoc 2017;6:e005918.

Ancheta IB, Battie CA, Volgman AS, Ancheta CV, Palaniappan L. Cardiovascular disease risk score: results from the Filipino-American women Cardiovascular Study. J Racial Ethn Health Disparities 2017;4:25–34.

Fan H, Li X, Zheng L, Chen X, Lan Q, Wu H, et al. Abdominal obesity is strongly associated with cardiovascular disease and its risk factors in elderly and very elderly community-dwelling Chinese. Sci Rep 2016;6:21521.

Yang X, Gu D. Response by Yang and Gu to Letter Regarding Article, “Predicting the 10-Year Risks of Atherosclerotic Cardiovascular Disease in Chinese Population: The China-PAR Project (Prediction for ASCVD Risk in China)”. Circulation 2017;135:e822–c3.

Hu Y, Zheng S, Zhao J, Deng X, Tan J, Butlin M, et al. The relationship between obesity phenotypes and cardiovascular risk in a Chinese cohort. The Pulse of Asia (Basel), Shanghai, China: Pulse; 2019, p. 40.